Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 6Active not recruiting 3Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

pembrolizumab 247Nivolumab 144Cyclophosphamide 137Cisplatin 137Paclitaxel 115Carboplatin 111Gemcitabine 100Radiotherapy 86Dexamethasone 84Docetaxel 79Ipilimumab 70atezolizumab 68Doxorubicin 63Fluorouracil 60Blood Specimen Collection 60Bevacizumab 59Etoposide 55fludarabine 54Rituximab 54Oxaliplatin 52Prednisone 51Lenalidomide 51Surveys and Questionnaires 50Cetuximab 47Standard of Care 46Capecitabine 46Radiosurgery 44Magnetic Resonance Spectroscopy 44lenvatinib 43durvalumab 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × quizartinib × 1 year × Clear all
NCT04687761 2026-05-13

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

PETHEMA Foundation

Phase 1/2 Completed
113 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04107727 2026-03-24

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

PETHEMA Foundation

Phase 2 Completed
273 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡